Drug Profile
Tarlatamab - Amgen
Alternative Names: AMG-757Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; BeiGene
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Small cell lung cancer
- Phase I Prostate cancer
- No development reported Malignant melanoma
Most Recent Events
- 26 Feb 2024 Amgen plans the phase III DeLLphi-305 trial for Small cell lung cancer (Combination therapy, Second-line therapy or greater) in China and other countries worldwide (IV, Infusion) in June 2024 (NCT06211036)
- 20 Feb 2024 Amgen initiates enrolment in the Phase-III DeLLphi-306 trial for Small cell lung cancer (Second-line therapy or greater) in Japan, South Korea and Taiwan (IV) (NCT06117774)
- 06 Feb 2024 Phase-I development is ongoing in Small-cell-lung-cancer (Combination therapy, Monotherapy, Second-line therapy or greater) in France, Germany, Japan, Netherlands, Spain, United Kingdom, USA, Switzerland, Poland, Australia (NCT03319940)